Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90001 in Pulmonary Fibrosis
NCT02510937Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of CC-90001 in pulmonary fibrosis (PF) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Adverse Events at 16 weeks, Dose interruptions, reductions, and discontinuation at 16 weeks and 6 more. Started Aug 2015; status: completed.
02
Drugs
CC-90001
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT02510937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510937.